PriceTargets.com logo

Xilio Therapeutics - XLO Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.03 As of 09/16/2026 11:04 AM ET
+0 (0.00%)

This chart shows the closing price for XLO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xilio Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XLO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XLO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Xilio Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.03.

This chart shows the closing price for XLO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 investment analysts is to sell stock in Xilio Therapeutics. This rating has held steady since July 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/18/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/17/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
9/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/2/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/6/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
7/17/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
7/1/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
6/15/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
5/26/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
5/8/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/1/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/6/2025Leerink PartnersUpgradeStrong-Buy
8/6/2025Leerink PartnersInitiated CoverageOutperform$28.00
11/8/2024Raymond James FinancialLower TargetOutperform ➝ Outperform$84.00 ➝ $56.00
7/10/2023Chardan CapitalReiterated RatingBuy
1/27/2023Morgan StanleyLower TargetOverweight$280.00 ➝ $140.00
12/21/2022Chardan CapitalInitiated CoverageBuy$98.00
11/15/2022GuggenheimLower Target$210.00
11/10/2022Raymond James FinancialLower TargetOutperform$434.00 ➝ $182.00
8/10/2022Morgan StanleyLower TargetOverweight$448.00 ➝ $280.00
1/10/2022HC WainwrightInitiated CoverageBuy
11/16/2021GuggenheimInitiated CoverageBuy
11/16/2021Raymond James FinancialInitiated CoverageOutperform$434.00
11/16/2021Morgan StanleyInitiated CoverageOverweight$448.00
11/16/2021TD CowenInitiated CoverageOutperform
(Data available from 9/16/2021 forward)

News Sentiment Rating

1.43 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Xilio Therapeutics logo
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $9.03
Low: $8.93
High: $9.02

50 Day Range

MA: $9.04
Low: $8.31
High: $9.50

52 Week Range

Now: $9.03
Low: $6.47
High: $12.74

Volume

1,424 shs

Average Volume

36,648 shs

Market Capitalization

$59.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Xilio Therapeutics?

The following Wall Street research analysts have issued research reports on Xilio Therapeutics in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for XLO.

What is the current price target for Xilio Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Xilio Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Xilio Therapeutics in the next year.
View the latest price targets for XLO.

What is the current consensus analyst rating for Xilio Therapeutics?

Xilio Therapeutics currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe XLO will underperform the market and that investors should sell shares of Xilio Therapeutics.
View the latest ratings for XLO.

What other companies compete with Xilio Therapeutics?

Other companies that are similar to Xilio Therapeutics include Compugen, Whitehawk Therapeutics, Protara Therapeutics, Eledon Pharmaceuticals and Keros Therapeutics. Learn More about companies similar to Xilio Therapeutics.

How do I contact Xilio Therapeutics' investor relations team?

The company's listed phone number is 857-524-2466 and its investor relations email address is [email protected]. The official website for Xilio Therapeutics is www.xiliotx.com. Learn More about contacing Xilio Therapeutics investor relations.